Jiangsu Bioperfectus Technologies Co., Ltd. (SHA:688399)
China · Delayed Price · Currency is CNY 78.71
-0.71 (-0.89%)
Jan 23, 2026, 3:00 PM CST
SHA:688399 Revenue
Jiangsu Bioperfectus Technologies had revenue of 81.93M CNY in the quarter ending September 30, 2025, a decrease of -9.61%. This brings the company's revenue in the last twelve months to 339.03M, down -14.13% year-over-year. In the year 2024, Jiangsu Bioperfectus Technologies had annual revenue of 349.61M, down -13.29%.
Revenue (ttm)
339.03M
Revenue Growth
-14.13%
P/S Ratio
19.65
Revenue / Employee
572.68K
Employees
592
Market Cap
6.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 349.61M | -53.57M | -13.29% |
| Dec 31, 2023 | 403.18M | -5.13B | -92.72% |
| Dec 31, 2022 | 5.53B | 2.70B | 94.95% |
| Dec 31, 2021 | 2.84B | 1.10B | 63.19% |
| Dec 31, 2020 | 1.74B | 1.45B | 502.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 2.81B |
| Novogene | 2.17B |
| Wuhan Hvsen Biotechnology | 1.67B |
| Kexing Biopharm | 1.52B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Beijing Konruns Pharmaceutical | 871.31M |
| R&G PharmaStudies | 789.45M |